English
Regional settings| Spread | 0.13 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 5.06 |
| Open | 5.18 |
| 1-Year Change | 8.37% |
| Day's Range | 5.18 - 5.4 |
Lantern Pharma Inc. is a clinical stage biopharmaceutical company. The Company is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.
BRIEF: For the fiscal year ended 31 December 2021, Lantern Pharma Inc. revenues was not reported. Net loss increased from $5.9M to $12.4M. Higher net loss reflects Research and development increase from $2.2M to $7.6M (expense), General and administrative - Balancing v increase of 99% to $4.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.95 to -$1.13.
